Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer (PRESAGE)
- Conditions
- Breast cancerMedDRA version: 20.0Level: PTClassification code: 10006187Term: Breast cancer Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2024-516282-37-00
- Lead Sponsor
- Institut De Cancerologie De L Ouest
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 100
1.Obtaining signed informed consent prior to any trial-specific procedure, 10.Social protection, 2.Between 18 and 40 yo, 3.Histologically proven invasive breast carcinoma, 4.Indication for adjuvant or neoadjuvant chemotherapy validated by pre-therapy PCR, 5.T0-T1-T2-T3, 6.N0-N1-N2a, 7.M0 after extension assessment according to French INCa recommendations, 8.AMH (anti-müllerian hormone) =1 ng/mL and/or AFC (antral follicle count) = 5 (on ultrasound: ovaries puncturable transvaginally),, 9.HIV serology negative
1.Previous breast cancer, 2.History of any other cancer in the last 5 years, with the exception of basal cell and squamous cell skin cancers, 3.Pregnancy in progress, 4.Pulmonary embolism less than 6 months old, 5.Deep vein thrombosis less than 6 months old, 6.Dementia or altered mental state, 7.Legal incapacity or limited legal capacity. Medical or psychological conditions preventing the subject from understanding the study and signing the consent form (art. L.1121-6, L.1211-8, L.1211-9).
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method